Literature DB >> 26381542

Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression.

Grazia Malaponte1, Sameh Hafsi1, Jerry Polesel2, Giancarlo Castellano3, Paola Spessotto4, Claudio Guarneri5, Silvana Canevari3, Santo S Signorelli6, James A McCubrey7, Massimo Libra8.   

Abstract

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoproliferative malignancies with variable patterns of behavior and responses to therapy. NHL development and invasion depend on multiple interactions between tumor cells and non-neoplastic cells. Such interactions are usually modulated by several cytokines. Accordingly, it was demonstrated that matrix-metalloproteinase (MMP)-2 and MMP-9 were activated in human lymphoid cell lines by interleukin-6 (IL-6). The activation of these enzymes is associated with tumor invasion and metastasis in human cancers. MMPs are also activated in several cancers by osteopontin (OPN), a secreted glycoprotein that regulates cell adhesion, migration, and survival. However, it is still unclear if MMPs play a role in NHL development and if their activation is determined by OPN and/or IL-6. In the present study, two groups of 78 NHL patients and 95 healthy donors were recruited for the analysis of OPN, MMP-2, MMP-9 and IL-6.Significant higher circulating levels of MMP-2, MMP-9, OPN and IL-6 were observed in NHL patients when compared to healthy donors. Similar data were obtained by analyzing the activity of both MMP-2 and MMP-9. The multivariate regression model indicates that, in both NHL cases and healthy donors, OPN is associated with the increase of MMP-2 and MMP-9 levels independently of IL-6. These data were first confirmed by “in silico” analyses and then by “in vitro” experiments conducted on peripheral blood mononuclear cells randomly selected from both NHL patients and healthy donors.Overall, our data suggest that the activation of MMPs in NHL development is mostly associated with OPN. However, IL-6 may play an important role in the lymphomagenesis through the activation of other molecular pathways. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer Cell Survival, Metastasis, Inflammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L. Semenza.

Entities:  

Keywords:  B-cell lymphomas; Interleukin-6; Matrixmetalloproteinase; Osteopontin

Mesh:

Substances:

Year:  2015        PMID: 26381542     DOI: 10.1016/j.bbamcr.2015.09.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  Occupational and environmental exposure to pesticides and cytokine pathways in chronic diseases (Review).

Authors:  Silvia Gangemi; Eliza Gofita; Chiara Costa; Michele Teodoro; Giusi Briguglio; Dragana Nikitovic; George Tzanakakis; Aristides M Tsatsakis; Martin F Wilks; Demetrios A Spandidos; Concettina Fenga
Journal:  Int J Mol Med       Date:  2016-09-02       Impact factor: 4.101

2.  Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.

Authors:  Ying Chen; Fengtao You; Licui Jiang; Jialu Li; Xuejun Zhu; Yangyi Bao; Xiang Sun; Xiaowen Tang; Huimin Meng; Gangli An; Bozhen Zhang; Lin Yang
Journal:  Oncotarget       Date:  2017-06-06

3.  NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.

Authors:  Claudio Guarneri; Valentina Bevelacqua; Jerry Polesel; Luca Falzone; Patrizia S Cannavò; Demetrios A Spandidos; Grazia Malaponte; Massimo Libra
Journal:  Oncol Rep       Date:  2017-01-10       Impact factor: 3.906

4.  [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].

Authors:  L Wu; Y Z Zhang; B Xia; X W Li; T Yuan; C Tian; H F Zhao; Y Yu; E Sotomayor
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-12-14

5.  Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?

Authors:  Federica Lovisa; Anna Garbin; Sara Crotti; Piero Di Battista; Ilaria Gallingani; Carlotta Caterina Damanti; Anna Tosato; Elisa Carraro; Marta Pillon; Erfan Mafakheri; Filippo Romanato; Enrico Gaffo; Alessandra Biffi; Stefania Bortoluzzi; Marco Agostini; Lara Mussolin
Journal:  Diagnostics (Basel)       Date:  2021-02-06

6.  Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Salvatore Crisafulli; Lucrezia Bertino; Andrea Fontana; Fabrizio Calapai; Ylenia Ingrasciotta; Massimiliano Berretta; Gianluca Trifirò; Claudio Guarneri
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

Review 7.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

8.  Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.

Authors:  Zhenzhen Chen; Liangshun You; Lei Wang; Xianbo Huang; Hui Liu; Ju Ying Wei; Li Zhu; Wenbin Qian
Journal:  J Exp Clin Cancer Res       Date:  2018-08-13

Review 9.  The Tumor Microenvironment of DLBCL in the Computational Era.

Authors:  Giuseppina Opinto; Maria Carmela Vegliante; Antonio Negri; Tetiana Skrypets; Giacomo Loseto; Stefano Aldo Pileri; Attilio Guarini; Sabino Ciavarella
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

10.  Pseudo-inflammatory manifestations of choroidal lymphoma resembling Vogt-Koyanagi-Harada disease: case report based on multimodal imaging.

Authors:  Kanae Fukutsu; Kenichi Namba; Daiju Iwata; Kazuomi Mizuuchi; Satoru Kase; Kayo Suzuki; Hiroshi Shimizu; Yukiko Shibata; Fumihiko Yamawaki; Masahiro Onozawa; Susumu Ishida
Journal:  BMC Ophthalmol       Date:  2020-03-10       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.